The Tech News Roundup’s Post

Delft-based OASYS NOW, the EU’s first AI-powered patient recruitment platform, has been announced as the winner of Slush 100 after pitching live on the international summit’s Startup Stage. The Dutch company wins €1M equity investment from two of Europe’s most prominent early-stage venture funds: General Catalyst and Cherry Ventures. Read more about it here: https://lnkd.in/g4pkN_bh Nima Salami, Sara Okhuijsen

Who are Europe's most active early-stage healthtech investors in 2024? European healthtech funding is back on the up in 2024 after two successive years of falling from the record $18.1m raised in 2021. Startups in the sector have picked up $10.4bn so far this year, according to Sifted data, an increase on the $9.7bn raised in 2023 (comparable Dealroom data). With more than a month left to play with, and a reporting lag that typically means a number of smaller rounds don’t get clocked until further down the line, that number’s only going to track north. But which VCs are driving this renewed funding story? Sifted dug into our proprietary data — and confirmed the numbers with the most active — to find out. 10. Speedinvest 9. Verve Ventures 8. SFC Capital 7. YZR Capital 6. Mercia Ventures 5. ... 4. ... 3. ... 2. ... 1. ... The top 5? Step this way for the full piece: https://lnkd.in/eew7-jFB

Venture capital firms have long served as the launchpads for innovation in the biotech sector, and their importance can never be overstated. Delving into the inner workings of pharma and biotech venture capital arms, like Third Rock Ventures and OrbiMed, has been beyond enlightening. It's impressive to see how these entities not only inject capital but also blend strategic and operational support to shepherd biotech startups to unprecedented growth. Among the remarkable bunch, firms like AbbVie Ventures exemplify the lifeblood of biotech innovation. By targeting early-stage therapeutics and enabling access to a wider internal network, they're quite literally nurturing the future of medicine. Then with Astellas Venture Management actively fuelling frontier science, it's clear just how these VC arms amplify progress in patient care. And JJDC's 50-year legacy? Through comprehensive support across various stages and sectors, they are bridging nascent ideas and market triumphs. It's in these stories that the true value of venture capitals shines—birthing not just businesses, but real-world solutions to pressing health challenges. This narrative of endeavour and expertise doesn't end here. Innovations in healthcare from giants like Bayer's Leaps or the newly established Regeneron Ventures remind us how VC's role in healthcare is evolving dramatically — from fertilising the seeds of startups to reaping the fruits of a healthier future. jasonbedfordlowe@hyperec.com or buzz me up on 02039102908. #Biotech #VentureCapital #Innovation

Biotech Wins Big: Atlas Venture’s New Fund and What It Means for the Industry Atlas Venture has just revealed a new and exciting $450 million fund, making it their fourteenth, to help fuel innovation in biotech. Over the past two years, the firm has launched 16 companies, recruited more than 100 executives, and played a key role in billion-dollar acquisitions by big pharma. Here are some more details on their strategy and capital: -Large Fund Secured: Atlas Venture raised a $450M biotech fund, channeled toward innovative biotech companies. -Atlas’ Major Deals: Atlas has launched 16 biotechs in the past two years with the help of their previous 2022 fund, plus $1B acquisitions by Eli Lilly and Company, GSK, and Novartis. -Focused Strategy: Backed IPOs like Disc Medicine; highlighting a disciplined, diverse approach. -Biotech Boom: Atlas joins Bain Capital Life Sciences, ARCH Venture Partners, and Forbion in recent big biotech fundraises. As excitement sparks with more money entering the industry, what could this mean for smaller sized biotechs? Which promising companies should investors keep their eye on? “Core to Atlas is a disciplined approach to our firm, funds, and portfolio,” Atlas says in a recent release. “We believe deeply in the power of a focused venture creation strategy, building biotech companies across the spectrum of disease areas, modalities, and business models.” Feel free to check out the article linked below. #AtlasVentures #Biotech #LifeSciences #VentureCapital #BiotechInnovation #HealthcareInvesting #Startups #Biopharma #BiotechFunding #PharmaDeals #FutureOfMedicine #ScienceInnovation #HealthTech #BiotechBoom #InvestInInnovation #MedicalBreakthroughs #FundingTheFuture #InnovationInHealth #BiotechStartups #PharmaInvesting #HealthCareAdvances #PrevailPartners

Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol. Burow is a managing director at ARCH, where she has been influential in building bold and well-capitalized startups. Her role behind the scenes in biotech earned her a spot on the third annual STATUS List, which recognizes leaders in health, medicine, and science. STAT spoke with Burow about what’s getting her fired up in the health care industry and how she’d change the dynamics between the drug companies and government. Read on by clicking below! #biotech #biopharma #startups #venturecapital #investing #investmentstrategy #healthcare #vc #drugdevelopment

📣 #Healthcare and #LifeSciences #startups: there's a new #VC #fund from Regeneron, led by Michael Aberman and Jay Markowitz. From the article: "Our goal is to cultivate an ecosystem where the next generation of #biotech companies can thrive, drawing on the lessons learned and successes achieved at Regeneron and throughout our careers,”Michael Aberman said in the release. “Together, we will strive to identify and support groundbreaking advancements that push the boundaries of what's possible in #science and #medicine.” Andrew Hwang Dylan Ozyjowski Ramesh Sethuraman

𝗦𝗽𝗮𝗻𝗶𝘀𝗵 𝗩𝗖 𝗰𝗹𝗼𝘀𝗲𝘀 $𝟮𝟬𝟬𝗠 𝗳𝘂𝗻𝗱 𝘄𝗶𝘁𝗵 𝗽𝗹𝗮𝗻 𝘁𝗼 𝗯𝗿𝗼𝗮𝗱𝗲𝗻 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 🌍💸 Asabys Partners has closed a fund of €180M ($200M) to go toward 12-15 startups across #medtech and #biopharma. Clara Campàs Moya, Founding & Managing Partner said, “The successful and oversubscribed close of our SAHII II fund allows us to continue investing in the Spanish life sciences ecosystem, while strategically broadening our focus to Europe and other global markets." #Asabys has already invested in 17 companies since launching in 2018. Though the #VC scene in #Medtech / #Biotech slowed somewhat following a #COVID19 funding sugar high back in 2021, recent reports suggest #venturecapital funding is once again heading north. Median deal sizes have "continued to tick higher across all stages” in H1 2024 according to a report by PitchBook. Things are on the up... 📈 Full article: https://lnkd.in/eg9qfTNN #medtech #biotech #medicaldevice #healthtech #executivesearch #recruitment #vc #venturecapital #startups #healthcare #venturefunding

🚀 Dive into the latest trends in European startup funding! February's seed wrap-up reveals a surge in investments, particularly in the healthcare sector, setting the stage for groundbreaking advancements. With €137m raised, healthtech maintains its dominance, presenting abundant opportunities for innovation and growth. Here's a closer look at some noteworthy ventures leading the charge: Bioptimus Paris-based biotech securing the largest round of €31.8m, pioneering the development of a universal AI foundation model in biology for biomedical innovation. TORTUS UK startup revolutionizing healthcare with its AI co-pilot for doctors, securing $4.2m from prominent investors Khosla Ventures and Entrepreneur First. Orbis Medicines Copenhagen-based startup focused on drug discovery for orally taken drugs, securing €26m from Forbion Capital Partners and Novo Holdings. Isomab Ltd British startup dedicated to developing antibody treatments for life-threatening diseases, raising £7.5m from Broadview Ventures and others, with a focus on peripheral ischaemia. The UK emerges as a powerhouse, reclaiming its seed crown, closely followed by France and Germany. Stay tuned as we delve into intriguing deals and emerging trends reshaping the startup landscape. #healthtech #startupfunding #healthcareinnovation #investment 💼🔬

🩻🇬🇧 London-headquartered Semble (formerly Heydoc) is an integrated clinical system that allows healthcare businesses of all sizes to manage every aspect of their practice. The investment will enable the company to consolidate its position in the UK market and expand its presence in France, where it launched earlier this month. 📈 Now, it has raised $15 million in a Series B funding round led by Mercia Ventures, with participation from Octopus Ventures, Smedvig Ventures, and Triple Point. With this round, the total funding raised by the company accounts for $27 million. 🤖 Read more here: https://lnkd.in/edDN3X57 Christoph Lippuner Mikael Landau Alex Gwyther #tech #funding #news #VC #investment #innovation #technology #startup #UKtech #UKstartup

#AI and #Biotech Disruptions: #Startups Redefining Health and Fitness Solutions 🎯 1️⃣ Refoxy Pharma Raises €9.1M Lead Investor: Boehringer Ingelheim Venture Fund With participation from: Apollo Health Ventures, NRW.BANK, HTGF | High-Tech Gründerfonds 🔗 Read more: https://lnkd.in/gp2Pr-xA 📍 Berlin, Germany ------------------------------------------------------------------------------------ 2️⃣ GROWL Secures $4.75M Lead Investor: Skip Capital With participation from: Kima Ventures, Teampact.ventures, Ciryl Gane, and others 🔗 Learn more: https://lnkd.in/gSvhhQFv 📍 Austin, Texas #FundingNews #SeedFunding #HealthTech #zefyron #startupdatabase